PYXS (Pyxis Oncology) Total Equity: $31.27 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PYXS Pyxis Oncology Inc PYXS
27 GF Score
Price $3.18
! 4 Warning Signs
View Full Analysis

What is Pyxis Oncology Total Equity?

Pyxis Oncology PYXS 27 Total Equity is $31.27 Mil as of Mar. 2026. GuruFocus rates PYXS with a GF Score™ of 27/100. The stock has 4 warning signs investors should review.

Pyxis Oncology's total equity for the quarter that ended in Mar. 2026 was $31.27 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Pyxis Oncology Total Equity Historical Data

* Premium members only.

The historical data trend for Pyxis Oncology's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pyxis Oncology Total Equity Chart

Pyxis Oncology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 261.31 160.82 125.70 120.75 53.41

Pyxis Oncology Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.10 87.64 68.78 53.41 31.27
PYXS
27GF Score
Pyxis Oncology Inc PYXS
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pyxis Oncology Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Pyxis Oncology's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=91.52-38.112
=53.41

Pyxis Oncology's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=64.3-33.032
=31.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $31.27 Mil mean?
Pyxis Oncology (PYXS) has a Total Equity of $31.27 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Pyxis Oncology and its competitors.
Is Pyxis Oncology's Total Equity too high?
Pyxis Oncology's current Total Equity is $31.27 Mil. Overall, Pyxis Oncology has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Pyxis Oncology's Total Equity compare to ORMP and CAMP?
Pyxis Oncology's Total Equity of $31.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Pyxis Oncology and its competitors. Pyxis Oncology's current Total Equity is $31.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pyxis Oncology stock overvalued right now?
Pyxis Oncology (PYXS) has a current Total Equity of $31.27 Mil. The current Total Equity is $31.27 Mil. Pyxis Oncology's overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Pyxis Oncology (PYXS), the current Total Equity is $31.27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pyxis Oncology Business Description

Address 321 Harrison Avenue, Boston, MA, USA, 02118
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
27GF Score

Get the complete analysis for PYXS

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.18
Price